Estrella Immunopharma, Inc. (ESLAW)

USD 0.05

(-45.12%)

Market Cap (In USD)

1.77 Million

Revenue (In USD)

-

Net Income (In USD)

-7.31 Million

Avg. Volume

-

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.05-0.0505
PE
-
EPS
-
Beta Value
-0.09
ISIN
US2975841121
CUSIP
297584112
CIK
1844417
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Cheng Liu Ph.D.
Employee Count
-
Website
https://www.estrellabio.com
Ipo Date
Details
Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.